Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
Status:
Completed
Trial end date:
2020-08-10
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety, tolerability and antiviral
activity of selgantolimod (formerly GS-9688) in virally suppressed chronic hepatitis B (CHB)
adults on oral antiviral (OAV) agents.